We are live on ! Find out more
AUTL icon

Autolus Therapeutics

95 hedge funds and large institutions have $261M invested in Autolus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 34 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.16% less ownership

Funds ownership: 63.3% → 63.14% (-0.16%)

7% less capital inflows, than outflows

Capital inflows: $27.3M | Capital outflows: $29.3M

14% less funds holding

Funds holding: 110 → 95 (-15)

15% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 34

40% less call options, than puts

Call options by funds: $87K | Put options by funds: $145K

65% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 23

Holders
95
Holders Change
-15
Holders Change %
-13.64%
% of All Funds
1.27%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
29
Reduced
34
Closed
23
Calls
$87K
Puts
$145K
Net Calls
-$58K
Net Calls Change
+$220K

AUTL Hedge Fund Activity: Q1 2025 in Review

95 of the 7,489 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2025, worth a combined $261M — down 34% from $395M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of AUTL and 8 opened new positions — a net loss of 15 holders — while 34 trimmed existing stakes and 29 added.

The largest buyer was Deep Track Capital, adding an estimated $7.37M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.

  • 95 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2025, down from 110 in Q4 2024.
  • Funds reported $261M of Autolus Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
  • 8 funds opened new Autolus Therapeutics positions in Q1 2025 and 23 closed out, a net change of -15 holders.
  • The largest Autolus Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $7.37M added.
  • The largest Autolus Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $11.1M sold.

Based on aggregated 13F filings for Q1 2025.